387 A Phase II, multicenter study of the safety and efficacy of LAG525 in combination with spartalizumab in patients with advanced malignancies
Publication
, Conference
Lin, C-C; Garralda, E; Schöffski, P; Hong, D; Siu, L; Martin, M; Maur, M; Hui, R; Soo, R; Chiu, J; Zhang, T; Ma, B; Kyi, C; Tan, D; Kwak, E ...
Published in: Regular and young investigator award abstracts
November 2020
Duke Scholars
Published In
Regular and young investigator award abstracts
DOI
Publication Date
November 2020
Publisher
BMJ Publishing Group Ltd
Conference Name
35th Anniversary Annual Meeting (SITC 2020)
Related Subject Headings
- 3211 Oncology and carcinogenesis
- 3204 Immunology
Citation
APA
Chicago
ICMJE
MLA
NLM
Lin, C.-C., Garralda, E., Schöffski, P., Hong, D., Siu, L., Martin, M., … Braud, F. D. (2020). 387 A Phase II, multicenter study of the safety and efficacy of LAG525 in combination with spartalizumab in patients with advanced malignancies. In Regular and young investigator award abstracts. BMJ Publishing Group Ltd. https://doi.org/10.1136/jitc-2020-sitc2020.0387
Lin, Chia-Chi, Elena Garralda, Patrick Schöffski, David Hong, Lillian Siu, Miguel Martin, Michela Maur, et al. “387 A Phase II, multicenter study of the safety and efficacy of LAG525 in combination with spartalizumab in patients with advanced malignancies.” In Regular and Young Investigator Award Abstracts. BMJ Publishing Group Ltd, 2020. https://doi.org/10.1136/jitc-2020-sitc2020.0387.
Lin C-C, Garralda E, Schöffski P, Hong D, Siu L, Martin M, et al. 387 A Phase II, multicenter study of the safety and efficacy of LAG525 in combination with spartalizumab in patients with advanced malignancies. In: Regular and young investigator award abstracts. BMJ Publishing Group Ltd; 2020.
Lin, Chia-Chi, et al. “387 A Phase II, multicenter study of the safety and efficacy of LAG525 in combination with spartalizumab in patients with advanced malignancies.” Regular and Young Investigator Award Abstracts, BMJ Publishing Group Ltd, 2020. Crossref, doi:10.1136/jitc-2020-sitc2020.0387.
Lin C-C, Garralda E, Schöffski P, Hong D, Siu L, Martin M, Maur M, Hui R, Soo R, Chiu J, Zhang T, Ma B, Kyi C, Tan D, Cassier P, Sarantopoulos J, Weickhardt A, Carvajal R, Spratlin J, Esaki T, Rolland F, Akerley W, Deschler-Baier B, Sabatos-Peyton C, Chowdhury NR, Gusenleitner D, Kwak E, Askoxylakis V, Braud FD. 387 A Phase II, multicenter study of the safety and efficacy of LAG525 in combination with spartalizumab in patients with advanced malignancies. Regular and young investigator award abstracts. BMJ Publishing Group Ltd; 2020.
Published In
Regular and young investigator award abstracts
DOI
Publication Date
November 2020
Publisher
BMJ Publishing Group Ltd
Conference Name
35th Anniversary Annual Meeting (SITC 2020)
Related Subject Headings
- 3211 Oncology and carcinogenesis
- 3204 Immunology